Monte Rosa Therapeutics (GLUE) Net Cash Flow Growth (1y) (2021 - 2026)
Monte Rosa Therapeutics (GLUE) Net Cash Flow Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,681.27 Bn | 66,680.98 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 472.75 Bn | 467.96 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 122.14 Bn | 114.89 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.94 Bn | 50.76 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn | 53.46% |
| 10 | Monte Rosa Therapeutics | 2.28 Bn | 1.60 Bn | - | 120.57% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 120.57% |
| Dec 31, 2025 | -179.54% |
| Sep 30, 2025 | 728.35% |
| Jun 30, 2025 | -199.26% |
| Mar 31, 2025 | -419.16% |
| Dec 31, 2024 | 42.73% |
| Sep 30, 2024 | 39.48% |
| Jun 30, 2024 | 263.22% |
| Mar 31, 2024 | -816.59% |
| Dec 31, 2023 | 220.25% |
| Sep 30, 2023 | 38.64% |
| Jun 30, 2023 | 83.92% |
| Mar 31, 2023 | 98.53% |
| Dec 31, 2022 | -231.14% |
| Sep 30, 2022 | -13.05% |
| Jun 30, 2022 | -118.32% |
| Mar 31, 2022 | -263.94% |
| Dec 31, 2021 | -77.63% |
| Sep 30, 2021 | -75.02% |